Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Brilinta Advisory Cmte. Nod Creates Postmarketing Study Quandary For FDA

Aug 02 2010

• By The Pink Sheet

Related Content

Brilinta Panel Leaves FDA With The Task Of Crafting Labeling That Describes Poor U.S Efficacy Results

Jul 28 2010

IoM Report On Postmarketing Study Ethics Could Drive Broad Overhaul Of Informed Consent

Jul 12 2010

Additional Topics

BioPharmaceutical

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window